Literature DB >> 31401568

Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Cristina Saavedra1,2, Angela Lamarca1,3, Richard A Hubner1,3.   

Abstract

A 70-year-old man reported progressive weight loss, fatigue and a generalised rash. The rash was consistent with necrolytic migratory erythema, further investigations were performed and the patient was diagnosed with a mass in the tail of the pancreas, in keeping with a localised glucagonoma. Somatostatin analogue therapy was started for symptom control, leading to complete resolution of the skin rash and an improvement in constitutional symptoms. Subsequently, the pancreatic lesion was excised, and pathology assessment confirmed the diagnosis of well-differentiated neuroendocrine tumour with high expression of glucagon compatible with glucagonoma. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; pancreatic cancer

Mesh:

Substances:

Year:  2019        PMID: 31401568      PMCID: PMC6700568          DOI: 10.1136/bcr-2018-229115

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome.

Authors:  Erik K Alexander; Malcolm Robinson; Maryjane Staniec; Robert G Dluhy
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

2.  Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration.

Authors:  W C Santangelo; R H Unger; L Orci; M I Dueno; J J Popma; G J Krejs
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

3.  Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.

Authors:  G Boden; I G Ryan; B L Eisenschmid; J J Shelmet; O E Owen
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

4.  Rapid resolution of necrolytic migratory erythema after glucagonoma resection.

Authors:  A P Smith; A Doolas; E D Staren
Journal:  J Surg Oncol       Date:  1996-04       Impact factor: 3.454

5.  Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema.

Authors:  A P Bewley; J S Ross; C B Bunker; R C Staughton
Journal:  Br J Dermatol       Date:  1996-06       Impact factor: 9.302

Review 6.  Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.

Authors:  Emily P Tierney; Joanna Badger
Journal:  MedGenMed       Date:  2004-09-10

7.  Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.

Authors:  Roy Eldor; Benjamin Glaser; Merav Fraenkel; Victoria Doviner; Asher Salmon; David J Gross
Journal:  Clin Endocrinol (Oxf)       Date:  2011-05       Impact factor: 3.478

Review 8.  A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.

Authors:  Starling Tolliver; Jaqueline Graham; Benjamin H Kaffenberger
Journal:  Int J Dermatol       Date:  2018-02-16       Impact factor: 2.736

9.  Necrolytic migratory erythema.

Authors:  Réka K Kovács; Irma Korom; Attila Dobozy; Gyula Farkas; Jeno Ormos; Lajos Kemény
Journal:  J Cutan Pathol       Date:  2006-03       Impact factor: 1.587

10.  The glucagonoma syndrome. Clinical and pathologic features in 21 patients.

Authors:  R A Wermers; V Fatourechi; A G Wynne; L K Kvols; R V Lloyd
Journal:  Medicine (Baltimore)       Date:  1996-03       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.